Valneva SE (NASDAQ:VALN – Get Rating) was the recipient of a large increase in short interest during the month of December. As of December 30th, there was short interest totalling 31,900 shares, an increase of 48.4% from the December 15th total of 21,500 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 4,100 shares, the short-interest ratio is currently 7.8 days.

Analyst Upgrades and Downgrades

VALN has been the topic of several recent analyst reports. The Goldman Sachs Group lowered shares of Valneva from a "buy" rating to a "neutral" rating in a report on Friday, September 23rd. HC Wainwright lowered their price objective on shares of Valneva from $27.00 to $25.00 in a research report on Monday, December 5th.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its holdings in Valneva by 85.9% in the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock worth $569,000 after purchasing an additional 7,664 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Valneva during the first quarter valued at approximately $858,000. UBS Group AG bought a new stake in Valneva in the second quarter valued at $31,000. Finally, General American Investors Co. Inc. bought a new stake in Valneva in the third quarter valued at $3,768,000. 15.83% of the stock is currently owned by institutional investors and hedge funds.

Valneva Stock Down 1.1 %

Valneva (NASDAQ:VALN – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of ($0.14) by $1.47. The business had revenue of $157.92 million for the quarter, compared to the consensus estimate of $78.52 million. On average, sell-side analysts predict that Valneva will post -1.19 earnings per share for the current fiscal year.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Articles

• Get a free copy of the StockNews.com research report on Valneva (VALN)
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth
• Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.